title: [Screening for prodromes of chemotherapy-induced vomiting and correlation between prodromes and chemotherapy-induced vomiting in lung cancer patients].
abstract: OBJECTIVE
  To explore prodromes of chemotherapy-induced vomiting (CIV) and their association with CIV in lung cancer patients.
  
  
  METHODS
  The prodromes of CIV in 250 lung cancer patients were analyzed. Logistic regression was used to determine the symptoms most likely correlated with CIV. One hundred fifty-seven patients received medical interventions. The development of correlative symptoms and occurrence of CIV between the intervention and non-intervention groups was analyzed.
  
  
  RESULTS
  Among the 250 patients with the prodromes of CIV, the incidence rate of CIV was 67.2%. Logistic regression indicated that nausea, constipation, insomnia, hiccups, anorexia, and history of drinking were correlated with CIV (P < 0.05 for all). Among the 20 symptoms observed in this study, the incidence rates of relatively common symptoms were nausea (72.0%), anorexia (68.4%), taste changes (48.8%), constipation (45.6%), abdominal distension (45.6%), stomach distension(40.4%), and insomnia (40.0%). The incidence rats of all symptoms except hiccups before and after intervention had significant difference (P < 0.05 for all). The incidence rates of CIV were 30.0% in the intervention group and 50.6% in the non-intervention group, with a significant difference between the two groups (P = 0.009).
  
  
  CONCLUSIONS
  Prodromes of CIV are closely related to the occurrence of CIV. Timely intervention for prodromes of CIV can reduce the incidence rate of CIV during chemotherapy in lung cancer patients.
authors.affiliation: Medical Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
authors.forename: Jiuqin
authors.initials: J
authors.lastname: Lu
authors.affiliation: Medical Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
authors.forename: Liangliang
authors.initials: L
authors.lastname: Ma
authors.affiliation: Medical Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
authors.forename: Xinyue
authors.initials: X
authors.lastname: Wang
authors.affiliation: Medical Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
authors.forename: Zhujun
authors.initials: Z
authors.lastname: Liu
authors.affiliation: Medical Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.affiliation: Medical Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China. Email: likai5@medmail.com.cn.
authors.forename: Kai
authors.initials: K
authors.lastname: Li
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D008175:Lung Neoplasms / Q000453:epidemiology*; D009325:Nausea / Q000139:chemically induced / Q000175:diagnosis / Q000453:epidemiology; D051381:Rats; D014839:Vomiting / Q000139:chemically induced / Q000175:diagnosis* / Q000453:epidemiology
chemical_list: D000970:Antineoplastic Agents